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Introduction {#sec1}
============

The pancreas is an endoderm-derived organ that has several crucial roles, among them, controlling levels of glucose in the blood by producing insulin from β cells and aiding digestion by secreting digestive enzymes to the digestive system. The pancreas develops from a group of progenitor cells, originating from the endoderm developing gut, under the control of signaling pathways that determine its correct position and size ([@bib42]; [@bib46]). One of these determinant signaling molecules is Bmp, which has various roles in pancreas development. These roles include the regulation of pancreatic size by controlling liver and pancreas fates, partly by restricting the expression of *pdx1*, an important top hierarchical gene present in pancreatic progenitor cells ([@bib42]; [@bib46]). In zebrafish, and according to this model, *bmp2b* expressed and secreted from the lateral plate mesoderm generates a gradient at which high levels of Bmp2b restrict pancreatic size, favoring liver fate and establishing the development of the pancreas in a region aligned with the midline of the embryo ([@bib11], [@bib12]). In this context, Bmp signaling works as negative regulator of pancreas development. Interestingly, it has been long postulated that the notochord, located at the midline of the embryo, dorsal to the pancreas, has a pro-pancreatic function ([@bib42]; [@bib46]). Part of these observations derive from studies in which the notochord was surgically removed from chicken embryos, showing that in its absence, pancreatic markers such as *insulin* were defectively expressed, as well as early progenitor markers such as *Pdx1* ([@bib24]). These results suggest that a non-autonomous signal must emanate from the notochord to induce pancreatic fate. One possibility is that activin βB and fibroblast growth factor 2 (*FGF2*), expressed in the notochord, might have a role in pancreatic induction via repression of *SHH* expression in the endoderm ([@bib18]). Nevertheless, ectopic pancreatic tissue is not observed in the endoderm of Shh mutant embryos ([@bib19]), suggesting that inhibition of Shh signaling is permissive, rather than instructive, for pancreas fate ([@bib35]). A complementary hypothesis to be addressed is the presence of a Bmp antagonist expressed in the notochord that might be required for proper pancreatic induction; however, little is known about how Bmp signaling is modulated in the endoderm to effectively determine pancreatic size and position.

In zebrafish, one of the most notochord-specific Bmp antagonists is Noggin2 (Nog2) ([@bib17]). *nog2* starts to be expressed by the end of gastrulation (10 h post-fertilization \[hpf\]) in the zebrafish axial mesoderm, which shortly gives rise to the notochord ([@bib17]). This expression is maintained up to the 18-somite stage (16 hpf), when the transcript slowly starts to disappear, and persists until 30 hpf in the posterior tip of the notochord. In this work, we disrupted the function of *nog2*, observed consistent impairment in the number of pancreatic progenitor cells and insulin-expressing cells, and showed *nog2* to be an important Bmp antagonist required for pancreatic development. The introduction of an enhancer blocking insulator ([@bib5]) downstream of *nog2* also impaired β cell differentiation and reduced the number of pancreatic progenitor cells, suggesting the existence of an enhancer required for the *nog2* pancreatic function. By analyzing histone modifications associated with enhancer activity (histone H3 lysine 27 acetylation \[H3K27ac\] and histone H3 lysine 4 monomethylation \[H3K4me1\]) ([@bib8]; [@bib34]; [@bib44]) and performing circular chromosome conformation capture coupled with next-generation sequencing (4C-seq) ([@bib55]), we identified a *nog2* notochord enhancer, among others. To further demonstrate that the notochord enhancer is crucial for the *nog2* pancreatic function, we targeted it using CRISPR-Cas9, inducing genomic deletions ([@bib33]); complementing these assays, we used Cas9 endonuclease dead (dCas9) fused to a KRAB repressor domain (dCas9KRAB) ([@bib50]) and observed β cell differentiation impairment. Moreover, in heteroallelic mutant embryos for partial deletion of the notochord enhancer, we observed a reduced number of pancreatic progenitor cells and β cells when performing immunostaining for Nkx6.1 and insulin, respectively. In addition, we traced Nog2 *in vivo* and observed its diffusion from the notochord to the pancreatic progenitor domain, supporting its non-autonomous function in pancreas development. To understand whether this mechanism could also be present in mammals, we explored the human and mouse *Nog* regulatory landscapes, identifying notochord enhancers. Overall, these results suggest that *Nog* has acquired a notochord enhancer, most likely in the basis of the vertebrate phylogeny, that contributes to the crucial function of the notochord as an important signaling center for the development of complex organs such as the pancreas.

Results {#sec2}
=======

*nog2* Controls Non-autonomously the Embryonic Endocrine Pancreas Size {#sec2.1}
----------------------------------------------------------------------

*nog2* encodes a zebrafish Bmp antagonist that starts to be expressed at 10 hpf in the primordium of the notochord ([@bib17]). To identify possible non-coding genetic modifications affecting pancreas development, we mobilized a transposable element containing a potent enhancer blocking insulator ([@bib5]). We found a novel integration of this construct (ED301) located 2 kb downstream of *nog2* (*nog2*^ED301^) ([Figure 1](#fig1){ref-type="fig"}A; [Figure S1](#mmc1){ref-type="supplementary-material"}). Homozygous embryos for this integration showed a decrease of *nog2* expression at 10 hpf that was detected by qPCR ([Figure 1](#fig1){ref-type="fig"}B). To determine whether the downregulation of *nog2* could affect pancreas development, we performed *in situ* hybridization for *insulin* and determined that its area of expression was reduced in *nog2*^ED301^ homozygous embryos ([Figures 1](#fig1){ref-type="fig"}C and 1D) compared with control embryos. Next, to determine whether the phenotype observed in pancreas development was caused by the action of the insulator, we injected Cre recombinase in homozygous embryos for the *nog2*^ED301^ integration and performed *in situ* hybridization for *insulin*. Cre recombinase targeted two *loxP* cassettes flanking the insulator in the ED301 construct ([Figure 1](#fig1){ref-type="fig"}A). In this experimental condition, we observed a rescue of the decreased area of *insulin* expression ([Figure 1](#fig1){ref-type="fig"}D). These results suggest that the ectopic insulator might be blocking a *cis*-regulatory element of *nog2* required for proper pancreas development. To validate *nog2* as an important gene controlling pancreas development, we generated a *nog2* mutant line (*nog2*^*mut*^) using the CRISPR-Cas9 targeting system. This mutant line shows a frameshift mutation in the *nog2* gene ([Figure S2](#mmc1){ref-type="supplementary-material"}A). Although *nog2* is not expressed at the shield developmental stage, when the dorsal/ventral axis of the zebrafish embryo is established by a ventral gradient of Bmp, it is known that ectopic expression of *nog2* interferes with Bmp signaling, causing dorsalization phenotypes ([@bib17]). Therefore, to test whether the *nog2*^*mut*^ frameshift mutation is a loss of function of the *nog2* gene, we injected mRNA of the frameshift version of *nog2* in zebrafish embryos. We did not observe a dorsalization phenotype, contrasting the wild-type (WT) version of *nog2* mRNA ([Figures S2](#mmc1){ref-type="supplementary-material"}C and S2D). These results show that *nog2*^*mut*^ is most likely a null mutant for *nog2*. We incrossed *nog2*^+/mut^, generating a mixture of WT, heterozygous, and homozygous embryos, and outcrossed *nog2*^+/mut^ with *nog2*^ED301/ED301^. In both cases, the resulting embryos had a significant decrease in the area of expression of *insulin*, demonstrating that *nog2* is required for the differentiation of a correctly sized pancreas ([Figure 1](#fig1){ref-type="fig"}D). The decrease of the area of expression of *insulin* could be caused by a decrease in the number of β cells or by a decrease in their size. To discriminate between these two possible scenarios, we injected a morpholino against *nog2* in a transgenic reporter line for *insulin* expression ([@bib13]) and observed a reduced number of β cells in the *nog2* morpholino-injected animals ([Figures S2](#mmc1){ref-type="supplementary-material"}E and S2F). In addition, we performed immunostaining for Nkx6.1, to label pancreatic progenitor cells, and for insulin, to label differentiated β cells, in homozygous embryos for the *nog2*^ED301^ integration. We observed that the numbers of both Nkx6.1 and insulin cells decreased compared with controls. A similar decrease in the average number of Nkx6.1- and insulin-expressing cells was also detected in a 50% mixed population of embryos carrying the heteroallelic combination of *nog2*^ED301/mut^ and *nog2*^+/ED301^ ([Figures 1](#fig1){ref-type="fig"}E to 1G). These results suggest that the reduced number of insulin-expressing cells might be the consequence of a smaller pancreatic progenitor domain, indicating that *nog2* is required for the development of a properly sized pancreas.Figure 1nog2 Is Required for Proper Pancreas Development(A) ED301 zebrafish line corresponds to an ED transposon integration containing a potent enhancer blocking insulator (yellow) and mapped 2 kb downstream of *nog2*. The *loxP* sequences are depicted as black triangles (see also [Figure S1](#mmc1){ref-type="supplementary-material"}). Scale bar represents 2 kilobases.(B) In the ED301 zebrafish line, *nog2* expression is downregulated, as detected by qPCR performed in three biological replicates of 30 embryos each (error bars represent SD; ^∗^p \< 0.05).(C) *In situ* hybridization of *insulin* in 48 hpf representative embryos from an outcross of nog2^ED301/ED301^ and nog2^+/mut^ lines compared with control embryos. Scale bar represents 80 μm.(D) Quantification of the insulin expression area detected by *in situ* hybridization in control (n = 194), nog2 ^ED301/ED301^ (n = 93), nog2^ED301/ED301^ injected with Cre recombinase (n = 32), nog2^+/mut^ incross (n = 115), and nog2^ED301/ED301^, nog2^+/mut^ outcross embryos (n = 36) at 48 hpf. Error bars represent SD; ^∗∗∗∗^p \< 0.0001.(E) Representative confocal images of 48 hpf zebrafish embryos counterstained with a DAPI nuclear marker (blue), an anti-insulin antibody marking β cells (red), and an anti-Nkx6.1 antibody marking pancreatic progenitor cells (green). Images represent the maximum-intensity z projection of several focal planes obtained in a Leica Sp5 confocal microscope using a 40× objective. Scale bars represent 20 μm.(F) Quantification of the number of insulin-expressing cells in nog2^ED301/ED301^ and nog2^ED301/ED301^, nog2^+/mut^ outcross embryos compared with controls (n ≥ 30). Error bars represent SD; ^∗∗∗∗^p \< 0.0001, ^∗∗^p \< 0.01.(G) Quantification of the number of nkx6.1-expressing cells in nog2 ^ED301/ED301^ and nog2^ED301/ED301^, nog2^+/mut^ outcross embryos compared with controls (n ≥ 18). Error bars represent SD; ^∗∗∗∗^p \< 0.0001, ^∗∗∗^p \< 0.001.

*nog2* Genomic Regulatory Landscape Contains a Notochord-Specific Enhancer {#sec2.2}
--------------------------------------------------------------------------

Nog proteins are well-known diffusible molecules that act as Bmp antagonists ([@bib22]). *nog2* function in pancreas development might be explained by its expression in the notochord and subsequent diffusion to the endoderm, which has a non-autonomous, pro-pancreatic role. The *nog2*^ED301^ zebrafish line contains an insulator integration in the genomic landscape of *nog2* that causes its transcriptional downregulation. This leads us to postulate that an essential enhancer for the *nog2* pancreatic function should be present in the *nog2* regulatory landscape, downstream of the insulator integration. To identify the possible *cis*-regulatory element that might be triggering the expression of *nog2* in the notochord, we analyzed the landscape of *nog2*, looking for regions of open chromatin, as determined by **A**ssay for **T**ransposase-**A**ccessible **C**hromatin using **seq**uencing (ATAC-seq), and enriched for H3K27ac and H3K4me1, two histone marks associated with enhancer activity ([Figures 2](#fig2){ref-type="fig"}A and 2B). Because these histone modifications probably occur before the onset of *nog2* expression, starting in the notochord at 10 hpf, we looked at histone marks at the developmental stages of dome, 80% epiboly, and 24 hpf ([@bib8]; [@bib34]). In addition, we performed 4C-seq using the *nog2* promoter as the point of view to identify the subset of putative *cis*-regulatory sequences that interact with the promoter of nog2 and therefore belong specifically to the regulatory landscape of this gene ([Figure S3](#mmc1){ref-type="supplementary-material"}A). Using these strategies, we defined 3 putative *nog2* enhancers ([Figure 2](#fig2){ref-type="fig"}B, E1 to E3). We performed enhancer transgenesis assays for these sequences and verified that all 3 sequences are enhancers, together recapitulating the early expression pattern of *nog2* ([Figure 2](#fig2){ref-type="fig"}C; [Figure S1](#mmc1){ref-type="supplementary-material"}E). Of the 3 sequences, E3 was shown to be a strong notochord enhancer; E2 was shown to be is a forebrain, hindbrain, and somite enhancer; and E1 was shown to be a strong ventral forebrain enhancer ([Figure 2](#fig2){ref-type="fig"}C).Figure 2*nog2* Genomic Regulatory Landscape Contains a Notochord-Specific Enhancer(A) Genomic landscape of *nog2*, represented in the University of California Santa Cruz Genomics Institute (UCSC) genome browser ([@bib23]), comprising more than 100 kb. The black track represents chromatin interaction points detected by 4C-seq using the *nog2* promoter as the viewpoint (red asterisk). Scale bar represents 25 kilobases.(B) Zoom-in in the locus of *nog2* comprising approximately 25 kb. Representation of the ED transposon integration 2 kb downstream of *nog2*. Purple (top), brown (middle), and blue (bottom) tracks represent the ATAC-seq and chromatin immunoprecipitation sequencing (ChIP-seq) signal for H3K27ac and H3K4me1, respectively, at three developmental times: 24 hpf, 80% epiboly (80 epi), and dome. The black track represents the 4C-seq signal at 24 hpf using the *nog2* promoter as the viewpoint. Pale blue boxes highlight selected sequences for enhancer activity assays (E1 to E3). Two replicates of 4C data are shown in [Figure S3](#mmc1){ref-type="supplementary-material"}. Scale bar represents 5 kilobases.(C) Representative images of GFP reporter lines for enhancers E1 to E3 (see also [Figure S1](#mmc1){ref-type="supplementary-material"}). Scale bars represent 100 μm.

Next, we wanted to address whether *nog2* can diffuse from the notochord to the pancreatic progenitor domain. To test this, first we built a construct containing a Nog2-encoded protein fused to GFP. To test whether the GFPNog2 fusion protein maintained its functionality, we injected GFP*nog2* mRNA in 1-cell-stage embryos and observed the presence of dorsalization phenotypes, as in the case of WT *nog2* mRNA ([Figures S2](#mmc1){ref-type="supplementary-material"}C and S2D). Then, we built a transposable element containing the *nog2*E3 notochord enhancer and a minimal promoter upstream of *GFPnog2* (*nog2*E3:GFP*nog2*) to be able to track Nog2 diffusion ([Figure 3](#fig3){ref-type="fig"}A; [Figure S2](#mmc1){ref-type="supplementary-material"}B). Upon injection of zebrafish embryos with this construct and Tol2 mRNA, we performed staining using an anti-Nkx6.1 antibody that labels pancreatic progenitor cells ([@bib6]; [@bib20]). We observed clear colocalization of GFP aggregates in the pancreatic progenitor domain ([Figure 3](#fig3){ref-type="fig"}A) in 16 of 20 embryos (80%), as analyzed by confocal microscopy, showing that Nog2 can diffuse from the notochord to the pancreatic field in the endoderm. These results contrast those of controls expressing only GFP ([Figure 3](#fig3){ref-type="fig"}B), in which GFP aggregates were not seen outside of the notochord in 18 analyzed embryos. These results help to explain the non-autonomous effect observed in the pancreas in the *nog2* loss-of-function assays.Figure 3Nog2 Diffuses from the Notochord to the Pancreatic Progenitor Domain(A) Representative confocal image of a 18 hpf zebrafish embryo injected with the *nog2*E3:GFP*nog2* construct. Of 20 embryos, 16 (80%) showed colocalization of GFPNog2 aggregates (green) with pancreatic progenitor cells, labeled with anti-Nkx6.1 antibody (white). Details of the colocalization can be observed in the inset (white box).(B) Representative confocal image of a 18 hpf zebrafish embryo injected with nog2E3:GFP (control), in which the pattern of GFP expression (green) is restricted to the notochord. None of 18 analyzed embryos displayed colocalization of GFP aggregates with Nkx6.1-labeled cells. Embryos were counterstained with the nuclear marker DAPI (blue), and the endocrine progenitor domain is delimited by a yellow dashed line (see also [Figure S2](#mmc1){ref-type="supplementary-material"}). Images represent the maximum-intensity z projection of several focal planes obtained in a Leica Sp5 confocal microscope using a 40× objective. Scale bars represent 30 μm.

The *nog2* Notochord Enhancer Is Required for Proper Pancreas Development {#sec2.3}
-------------------------------------------------------------------------

The *nog2*E3 notochord enhancer most likely controls the expression of *nog2* in the notochord and is required for pancreatic development. To address this hypothesis, we synthetized a pair of single-guide RNAs (sgRNAs) 237 bp apart (*nog2*E3 sg1 and sg2) to target the *nog2*E3 notochord enhancer and generate genomic deletions for this *cis*-regulatory sequence. Embryos injected with Cas9 and the combination of *nog2*E3 sg1 and sg2 showed somatic deletions ([Figure 4](#fig4){ref-type="fig"}A; [Figures S3](#mmc1){ref-type="supplementary-material"}E--S3G). *In situ* hybridization for *insulin* was performed in these injected embryos, together with controls injected with Cas9 alone, and the area of *insulin* expression was measured. We observed a decreased area of *insulin* expression for *nog2*E3 sg1 and sg2 ([Figures 4](#fig4){ref-type="fig"}A--4C). To validate these results, we injected a combination of *nog2*E3 sg1 and sg2 with dCas9-KRAB ([@bib50]). When compared with control embryos injected with dCas9-KRAB alone, we observed a reduction in the area of insulin expression ([Figures S3](#mmc1){ref-type="supplementary-material"}B--S3D), suggesting that the *nog2*E3 notochord enhancer is modulating the expression of *nog2* in this tissue and is required for proper pancreas development. Indeed, partial deletion of the *nog2*E3 notochord enhancer shows a tendency for decreased *nog2* expression ([Figure S4](#mmc1){ref-type="supplementary-material"}). Furthermore, we observed a decrease in the average number of Nkx6.1- and insulin-expressing cells in homozygous embryos for this deletion ([Figures 4](#fig4){ref-type="fig"}G--4I), recapitulating the phenotype seen in the *nog2*^ED301^ integration mutants. Accordingly, ectopic expression of *nog2* in the notochord should result in increased pancreas size. To test this, we injected the *nog2*E3:GFP*nog2* construct and measured the size of the area of expression of *insulin*, noticing an incremental change in the pancreatic field area ([Figures 4](#fig4){ref-type="fig"}D--4F). These results demonstrate that the *nog2*E3 notochord enhancer is required for the proper function of *nog2* in pancreatic development and to establish a correctly sized pancreas.Figure 4The *nog2* Notochord Enhancer Is Required for Proper Pancreas Development(A) Representation of the WT nog2E3 enhancer (above) and somatic deletions (below) generated by the injection of the Cas9 protein, together with sg1 and sg2 targeting two regions of the sequence 237 bp apart (see also [Figure S3](#mmc1){ref-type="supplementary-material"}).(B) *In situ* hybridization of *insulin* in 48 hpf representative embryos, injected with the Cas9 protein, and two sgRNAs compared with control embryos, injected with only Cas9. Scale bars represent 80 μm.(C) Quantification of the *insulin* expression area detected by *in situ* hybridization in injected embryos at 48 hpf compared with controls. Error bars represent SD; ^∗∗∗∗^p \< 0.0001. In all cases, n ≥ 97.(D) Diagram of the nog2E3:GFPnog2 construct used to achieve notochord-specific overexpression of GFPnog2 and the respective control.(E) *In situ* hybridization of *insulin* in 48 hpf representative embryos injected with nog2E3:GFPnog2 compared with control embryos. Scale bars represent 80 μm.(F) Quantification of the *insulin* expression area detected by *in situ* hybridization in injected embryos at 48 hpf compared with controls. Error bars represent SD; ^∗∗∗^p \< 0.001. In all cases, n ≥ 38.(G) Representative confocal images of 48 hpf zebrafish embryos counterstained with a DAPI nuclear marker (blue), an anti-insulin antibody marking β cells (red), and an anti-Nkx6.1 antibody marking pancreatic progenitor cells (green). Images represent the maximum-intensity z projection of several focal planes obtained in a Leica Sp5 confocal microscope using a 40× objective. Scale bars represent 20 μm.(H) Quantification of the number of insulin-expressing cells in nog2E3^del1/del2^ embryos compared with controls (n ≥ 19). Error bars represent SD; ^∗^p \< 0.05.(I) Quantification of the number of nkx6.1-expressing cells in nog2E3^del1/del2^ embryos compared with controls (n ≥ 13). Error bars represent SD; ^∗∗∗^p \< 0.001.

The Expression of *Nog* in the Notochord Is Conserved in Vertebrates and Is Mediated by Equivalent Notochord Enhancers {#sec2.4}
----------------------------------------------------------------------------------------------------------------------

Next, we wanted to understand whether *NOG* expression in humans could be controlled by a notochord enhancer. To clarify this, we screened the human *NOG* genomic landscape for putative enhancers, based on sequence conservation and SNPs associated with type 2 diabetes and hyperglycemic traits ([Figure 5](#fig5){ref-type="fig"}A) ([@bib38]). We selected 9 candidate human sequences (D12 to D10) ([Figure 5](#fig5){ref-type="fig"}A) to perform enhancer reporter assays in zebrafish and determined whether any of these sequences is a notochord enhancer. Preliminary results obtained by the generation of mosaic zebrafish transgenic embryos showed that sequence D10 was able to drive expression of GFP in the notochord ([Figure S5](#mmc1){ref-type="supplementary-material"}D). We confirmed this result by generating stable zebrafish transgenic reporter lines for the selected sequences ([Figure 5](#fig5){ref-type="fig"}A). Apart from the D10 notochord enhancer, we found that D5 is a somite, forebrain, and hindbrain enhancer; D6 is a forebrain and somite enhancer; and D9 has broad enhancer activity and does not show high tissue specificity ([Figure 5](#fig5){ref-type="fig"}B; [Figures S5](#mmc1){ref-type="supplementary-material"}A--S5D). Enhancers D5, D6, D9, and D10 were confirmed and obtained concordant expression patterns in at least two independent genomic integrations of the reporter constructs ([Figures S5](#mmc1){ref-type="supplementary-material"}A--S5D). Sequences D7, D11, and D12 showed unreproducible patterns, and D12 and D8 showed no expression of the reporter gene. The expression patterns of the different human enhancers correlate with the known expression of *Nog* in mice, chicken, and *Xenopus* ([Figure S5](#mmc1){ref-type="supplementary-material"}E), including the notochord and nervous system, suggesting that the *Nog* vertebrate genomic landscape has functionally similar *cis*-regulatory elements.Figure 5The Expression of *Nog* in the Notochord Is Conserved in Vertebrates and Is Mediated by Equivalent Notochord Enhancers(A) Genomic landscape of human *NOG*, comprising approximately 150 kb. Black vertical lines represent SNPs associated with diabetes from the Diabetes Genetics Replication and Meta-analysis (DIAGRAM) Consortium (p \< 0.02) ([@bib38]; [@bib39]). The dark blue track represents vertebrate conservation and shows multiple alignments of 100 vertebrate species and measurements of evolutionary conservation (phyloP) ([@bib41]). Dashed line boxes are putative enhancer sequences selected for enhancer assays. Sequences in pale blue shaded boxes showed reproducible expression patterns. D10 (green shaded box) showed enhancer activity in the notochord. Scale bar represents 50 kilobases.(B) Representative images of GFP reporter lines for enhancers D5, D6, D9, and D10 (see also [Figure S5](#mmc1){ref-type="supplementary-material"}). Scale bars represent 100 or 200 μm.(C) Genomic landscape of the human D10 sequence, showing vertebrate (blue track) and mouse conservation (green track) (above). Genomic landscape of mouse *Nog*, including the conserved mouse D10 (mD10) sequence, located approximately 150 kb downstream of the promoter (see also [Figures S5](#mmc1){ref-type="supplementary-material"} and [S6](#mmc1){ref-type="supplementary-material"}). Scale bars represent 500 basepairs or 50 kilobases.(D) Representative image of the GFP reporter line for the mouse enhancer mD10. Scale bar represents 100 μm.

We were able to align the human D10 enhancer with the genome of other mammal species, suggesting that this *cis*-regulatory element is conserved. The most distantly related species with which D10 can be aligned are two representatives of marsupials, opossum (*Monodelphis domestica*) and Tasmanian devil (*Sarcophilus harrisii*), that diverged from humans around 180 million years ago ([Figure S5](#mmc1){ref-type="supplementary-material"}F). Interestingly, in four analyzed cases---mouse, dog, armadillo, and opossum---the D10 ortholog sequences are always found in synteny with the respective *Nog* ortholog genes ([Figures S6](#mmc1){ref-type="supplementary-material"}A and S6B), suggesting that these conserved sequences belong to the regulatory landscape of *Nog*. Furthermore, looking at HiC data from human and mouse tissues, it is possible to appreciate that NOG and D10 enhancer, as well as the corresponding mouse ortholog sequences, are within the same topologically associating domain (TAD) ([@bib14]) in a genomic region enriched for chromatin interactions ([Figures S6](#mmc1){ref-type="supplementary-material"}C--S6F). Next, we wanted to understand whether the conserved D10 orthologs correspond to notochord enhancers. In mice, the D10 ortholog sequence is located 157 kb downstream of *Nog* ([Figure 5](#fig5){ref-type="fig"}C). We isolated this sequence, tested it for enhancer activity using reporter assays, and demonstrated that this sequence is also a notochord enhancer ([Figure 5](#fig5){ref-type="fig"}D). Overall, these results suggest that the regulatory mechanism for the expression of *Nog* in the notochord might be equivalent in many vertebrate lineages.

Discussion {#sec3}
==========

Non-autonomous cell signaling is crucial for proper organogenesis. It has been demonstrated that several signaling pathways regulate pancreatic development in vertebrates. Among them, Hedgehog signaling represses the expression of the pancreatic multipotent progenitor marker *Pdx1* during late gastrulation ([@bib49]). In mice, activin βB and *Fgf2* expressed in the notochord might repress *Shh* expression in the endoderm ([@bib18]). However, ectopic pancreatic tissue is not observed in *Shh* mutant embryos ([@bib19]), suggesting that Shh inhibition is permissive, rather than instructive, for pancreas fate ([@bib35]). Experiments of notochord ablation in chicken embryos showed that pancreatic development is impaired ([@bib24]). These results highlight the notochord as an important signaling center for pancreatic development. In subsequent experiments using coculture of mice tissues, it has been shown that the notochord is sufficient to trigger expression of *Pdx1* in the endoderm, but not *Insulin*, whereas cells from the dorsal aorta are able to trigger the expression of *Pdx1* and *Insulin*. These results further suggest that the notochord and the dorsal aorta have a role in the control of pancreas progenitor cells, whereas aorta endothelial cells have an extra role in the differentiation of β cells ([@bib30]). Here we show that *Nog* is expressed in the notochord, controlled transversely in humans, mice, and zebrafish by at least one notochord enhancer, and that *nog2* gain and loss of function in zebrafish correlate with an increase and a decrease of pancreatic differentiation, respectively. In addition, we show that Nog2 diffuses from the notochord to the pancreatic domain, as detected indirectly by an ectopic expression system ([Figure 3](#fig3){ref-type="fig"}). These results indicate that Nog is one of the crucial pro-pancreatic signaling molecules emanating from the notochord. In agreement with this, Nog is a well-known Bmp signaling inhibitor ([@bib17]), and this signaling pathway is known to antagonize pancreas differentiation ([@bib11], [@bib12]) while promoting liver differentiation. In this model, the Bmp2b gradient emanating from the lateral plate mesoderm is not enough for the establishment of a proper pancreatic progenitor domain by control of the expression of *pdx1*. Nog2 from the notochord, located in the midline, counteracts the lateral signaling of Bmp2b, allowing the proper placement and proper size of the pancreatic progenitor domain in the midline ([Figure 6](#fig6){ref-type="fig"}). In absence of Nog2 from the notochord, Bmp2b signaling is most likely expanded, resulting in a reduced pancreatic progenitor domain that will cause partial impairment of β cell development ([Figure 6](#fig6){ref-type="fig"}). These phenotypes are recapitulated by impairing a *nog2* notochord enhancer, either by the action of an insulator or by the deletion of the enhancer. Nevertheless, in these genetic backgrounds, the downregulation of *nog2* is more robustly detected in the insulator background, suggesting the existence of several notochord enhancers or that partial deletion of the enhancer results in partial loss of expression of *nog2*. In both cases, knockdown of *nog2* is sufficient to induce a pancreatic phenotype.Figure 6Proper Pancreas Development Requires the Expression of Nog2 in the Notochord(A) Diagram of the nog2 notochord enhancer driving expression of *nog*2. Nog2 diffusion from the notochord, located in the midline of the embryo, counteracts the signaling of Bmp2b from the lateral plate mesoderm, allowing the proper placement and proper size of the endocrine pancreas.(B) When the activity of the *nog2* notochord enhancer is disrupted, *nog2* expression in the notochord is reduced. In this case, Bmp2b signaling is expanded, impairing β cell development and reducing pancreas size.

Although *nog2* has a clear pro-pancreatic role during zebrafish development, null mutants for *nog2* do not show complete loss of pancreas differentiation. Chicken notochord ablation has been shown to induce complete loss of pancreatic differentiation ([@bib24]). Therefore, it is possible that apart from *nog2*, there might be synergistic action with other pro-pancreatic signaling molecules diffusing from the notochord.

In this work, we postulate that the function of *NOG* is conserved in humans. Supporting this, the genomic landscape of *NOG* contains a notochord enhancer, clearly showing the potential of this gene to be expressed in these cells. A study of the human notochordal transcriptome during embryogenesis was able to detect *NOG* expression during development ([@bib45]), specifically at a late developmental time in human pancreatic formation. This interpretation is strengthened by advances in *in vitro* differentiation of human β cells from human embryonic stem cells. Optimization protocols have empirically determined that the addition of NOG was able to improve the efficiency of such protocols, clarifying the importance of BMP inhibition in the proper development of the human pancreas ([@bib27]; [@bib28]; [@bib36]; [@bib54]). Cai and colleagues explored the role of NOG in human β cell differentiation, showing that the inclusion of NOG in the media resulted in inhibition of phosphorylation of Smad1/5/8, a BMP signaling transducer ([@bib10]). From an evolutionary point of view, it is known that the vertebrate phylum contains at least three distinct *Nog* genes: *Nog1*, *Nog2*, and *Nog3* ([@bib15]). In mammals, only *Nog1* was kept, most likely retaining all functions and expression patterns of the three ancestral genes from the vertebrate phylum. An interesting open question relates to the emergence of the *cis*-regulatory module of the notochord that in humans and mice is present in the landscape of *Nog*, the ortholog of the zebrafish *nog1*, whereas in zebrafish, the notochord enhancer is present in the landscape of *nog2*. This could be explained by the independent recruitment of recently evolved notochord enhancers, as observed in the rapid evolution of *cis*-regulatory sequences of the mammal liver ([@bib52]). An alternative explanation could be the existence of an ancestral regulatory module driving the expression of *Nog* in the notochord that upon gene duplication degenerated in particular *Nog* genes. In the tetrapod lineage, the notochord *cis*-regulatory elements were most likely kept in the landscape of *Nog1*, a scenario supported by (1) the high conservation of the enhancer from humans to marsupials ([Figure S6](#mmc1){ref-type="supplementary-material"}), (2) the expression of Nog1 in the notochord from humans to *Xenopus* ([Figure 5](#fig5){ref-type="fig"}; [Figure S5](#mmc1){ref-type="supplementary-material"}), and (3) the functional characterization of the mice and human *Nog* notochord enhancers. In contrast, the existence of the notochord enhancer in the landscape of zebrafish *nog2* suggests that this enhancer was kept in this locus in the ray-finned fish lineage. Most likely, the acquisition of the *Nog* notochord enhancer occurred after the divergence of urochordates, because expression of *Nog* is not detected in the sea squirt *Ciona intestinalis* or in a cephalochordate, the amphioxus *Branchiostoma lanceolatum*. Interestingly, insulin-producing cells in basal cephalochordates are not organized in a distinct organ and are instead disseminated in the gut ([@bib2]). Finally, and in light of the axochord hypothesis ([@bib9]), the *Nog* notochord enhancer might have an even more ancient origin. Supporting this hypothesis, the annelids *Terebratalia transversa* and *Platymeris dumerilii* show expression of Nog in the axochord, a structure reminiscent of the notochord that has a mixture of muscle and notochord double properties ([@bib32]; [@bib40]).

In summary, in this work, we demonstrate the transversal existence of a notochord enhancer in humans, mice, and zebrafish in the landscape of Nog, a known Bmp antagonist. We show that this enhancer is required for proper pancreas differentiation in the zebrafish, contributing to understanding of the notochord as an important signaling center required for the complex development of the vertebrate pancreas.

STAR★Methods {#sec4}
============

Key Resources Table {#sec4.1}
-------------------

REAGENT or RESOURCESOURCEIDENTIFIER**Antibodies**Mouse monoclonal anti-Nkx6.1Developmental Studies Hybridoma BankCat\# F55A12; RRID: [AB_532379](nif-antibody:AB_532379){#intref0010}Rabbit polyclonal anti-insulinabcamCat\# ab210560**Deposited Data**4C-seq dataThis paperENA: PRJEB36984UCSC session with 4C-seq processed bedgraph tracks (smoothened to windows containing 30 fragments)This paper<http://genome-euro.ucsc.edu/cgi-bin/hgTracks?db=danRer7&lastVirtModeType=default&lastVirtModeExtraState=&virtModeType=default&virtMode=0&nonVirtPosition=&position=chr24%3A40302659%2D40356334&hgsid=239502130_A8rG2FyY9qsTK3VDD7dRiuUMjRi5>**Experimental Models: Organisms/Strains**Zebrafish: WT ABThis paperN/AZebrafish: WT TUThis paperN/AZebrafish: nog2ED301This paperN/AZebrafish: nog2mutThis paperN/AZebrafish: nog2E3del1/del2This paperN/AZebrafish: Tg (Ins:GFP)This paperN/AZebrafish: nog2E1:GFPThis paperN/AZebrafish: nog2E2:GFPThis paperN/AZebrafish: nog2E3:GFPThis paperN/AZebrafish: NOGD10:GFPThis paperN/AZebrafish: NOGD5:GFPThis paperN/AZebrafish: NOGD6:GFPThis paperN/AZebrafish: NOGD9:GFPThis paperN/AZebrafish: mD10:GFPThis paperN/A**Oligonucleotides**See [Table S1](#mmc2){ref-type="supplementary-material"} for primers and oligonucleotides used in this paper**Recombinant DNA**Zebrafish Enhancer Detection (ZED) Vector[@bib4]N/ApminiTol2- Z48-Gw-CARGFP[@bib4]N/ApDR274[@bib21]Addgene \#42250nog2E3:GFPnog2This paperN/A**Software and Algorithms**ImageJ[@bib48]<https://imagej.nih.gov/ij/>Graphpad PrismN/A<https://www.graphpad.com/>bowtie[@bib31]<http://bowtie-bio.sourceforge.net/index.shtml>Bedtools[@bib43]<https://github.com/arq5x/bedtools2>4C-seq processing perl scriptThis paperAvailable upon request to Juan Tena (<jjtenagu@upo.es>)**Other**Fastqc reports from the raw 4C-seq fastq files from this studyThis paper[Data S1](#mmc3){ref-type="supplementary-material"}

Resource Availability {#sec4.2}
---------------------

### Lead Contact {#sec4.2.1}

Further information and requests for resources and reagents should be directed to and will be fulfilled by the Lead Contact, José Carlos Ribeiro Bessa (<jose.bessa@ibmc.up.pt>)

### Materials Availability {#sec4.2.2}

All unique/stable reagents generated in this study are available from the Lead Contact with a completed Materials Transfer Agreement.

### Data and Code Availability {#sec4.2.3}

Raw reads from 4C experiments (fastq files of the 2 replicates) are accessible in the European Nucleotide Archive (ENA, <https://www.ebi.ac.uk/ena>, project PRJEB36984, study ERP120260, runs ERR3964955 and ERR3964956). The processed signal is available for visualization in the following UCSC genome browser session <http://genomeeuro.ucsc.edu/s/vdr/danRer7_4Cseq_nog2>. Perl script for processing 4C seq data is available upon request.

Experimental Model and Subject Details {#sec4.3}
--------------------------------------

### Zebrafish {#sec4.3.1}

Zebrafish (Danio rerio) fish were handled according to European animal welfare regulations and standard protocols. The Animal Facility of the i3S is licensed by the Portuguese official veterinary department (DGAV) and accredited by the AAALAC (June, 2018), complies with Portuguese law (Portaria 1005/02 and Portaria 1131/97), the 2010/63/EU Directive, and follows the FELASA (Federation of European Laboratory Animal Science Associations) guidelines and recommendations concerning laboratory animal welfare. The current project is licensed by DGAV (reference: 0421/000/000/2016). Wild-Type (WT) zebrafish animals from AB or TU strain were used in this study. The following genotypes were used, as described in the text and [Key Resources Table](#sec4.1){ref-type="sec"}: nog2^ED301^, nog2^mut^, nog2E3^del1/del2^, Tg (Ins:GFP), nog2E1:GFP, nog2E2:GFP, nog2E3:GFP, NOGD10:GFP, NOGD5:GFP, NOGD9:GFP and mD10:GFP. Adult animals are kept at a controlled temperature (25°C) and under a 14h light-8h dark photoperiod. Recirculated water is continuously monitored regarding pH (7), salinity (900 μs) and temperature (28°C) values. In order to obtain zebrafish embryos, adult zebrafish were bred in ratios of 3 females to 2 males or 1 male to 1 female, depending on the purpose of the experiment. Embryos ranging from 16hpf to 48hpf were used.

Method Details {#sec4.4}
--------------

### Zebrafish transgenesis {#sec4.4.1}

ED301 line was generated as described by [@bib5]. Enhancer reporter assays were performed by cloning the selected genomic fragments into the ZED vector ([@bib4]). For the mouse sequence mD10 only, the pminiTol2- Z48-Gw-CARGFP vector was used ([@bib4]). Briefly, genomic regions of interest were PCR amplified using iMAXII polymerase and specific primers ([Table S1](#mmc2){ref-type="supplementary-material"}). TA cloning was used to introduce PCR products in the pCR8/GW/TOPO vector, as described in the pCR8/GW/TOPO TA Cloning Kit (ThermoFisher Scientific). To clone these sequences in the destination vectors, the Gateway LR Clonase II Enzyme mix (ThermoFisher Scientific) and respective protocol was used. Vectors where purified using phenol:cloroform and injected in one-cell-stage zebrafish embryos (AB strain), together with mRNA encoding Tol2 protein, in a 1:1 ratio and a final concentration of 25 ng/ul each. Injected embryos showing reporter expression were grown to adulthood and germinal line transmission was determined by outcrossing injected fish with wild-type animals and isolating F1 embryos with GFP expression. Embryos were kept in E3 medium with 0.003% 1-phenyl-2-thiourea (SigmaAldrich) to prevent pigmentation and were staged according to [@bib25]. Embryos showing GFP expression were anesthetized by adding tricaine (ethyl -3-aminobenzoate; SigmaAldrich) to the E3 medium, and expression patterns were documented at 18-24 hpf, using the Leica M205 stereomicroscope. Post-imaging analysis was done in Fiji-ImageJ ([@bib48]). Stable transgenic lines were selected to grow and maintained by outcrossing with wild-type animals.

### Genomic DNA extraction {#sec4.4.2}

Batches of embryos were incubated with Chelex 100 sodium form resin (Sigma \#C7901 25 gr) 5% in TE buffer and with proteinase K 1 mg/mL (ThermoFisher Scientific), at 56°C for 3 hours. After that, proteinase K activity was inactivated by incubating the samples at 100°C for 10 minutes.

### Cas9 targeting, sgRNA synthesis, mutant generation {#sec4.4.3}

The sgRNAs targeting the coding regions of *nog2* and the regions flanking nog2E3 ([Table S1](#mmc2){ref-type="supplementary-material"}) were designed using the Crisprscan software ([@bib37]). These oligonucleotides were annealed *in vitro* by denaturation at 95°C for 5 min followed by slow cooling at RT. Annealed oligonucleotides (1:10) were further inserted into 100ng of pDR274 vector ([@bib21]; Addgene plasmid \#42250) previously cut with BsaI (Anza, ThermoScientific). pDR274 vectors carrying sgRNA sequences were linearized with HindIII, purified with phenol:chloroform and transcribed with T7 RNA polymerase (ThermoFisher Scientific). sgRNAs were purified following the mRNA purification protocol previously described ([@bib4]). To achieve *nog2* knockdown, one- cell-stage zebrafish embrycos were injected with Cas9 protein (PNA Bio Inc) (150 250 ng/ul) and 1 sgRNA (80125 ng/ul), targeting the coding region of *nog2* (sg1*nog2*, [Table S1](#mmc2){ref-type="supplementary-material"}). To perform the nog2E3 enhancer knockdown, embryos were coinjected with a mixture containing a combination of either Cas9 protein or dCas9-KRAB mRNA and 2 sgRNAs (80125 ng/ul each) (sg1E3, sg2E3, [Table S1](#mmc2){ref-type="supplementary-material"}). In both cases, zebrafish mutants for nog2E3 were generated using the combination of sgRNA1 and sgRNA2. Enhancer deletion in zebrafish was detected by PCR with HOT FIREPol® DNA Polymerase (Solis BioDyne) using primers flanking the region of interest (see [Figure S3](#mmc1){ref-type="supplementary-material"} and [Table S1](#mmc2){ref-type="supplementary-material"}). PCR product was analyzed by electrophoresis in 2% agarose gel, and further confirmed by Sanger sequencing. Injected embryos were grown and adult fish fins were cut to perform genomic DNA extraction and genotyping as described above (see [Figure S4](#mmc1){ref-type="supplementary-material"} and [Table S1](#mmc2){ref-type="supplementary-material"}). One heterozygous male and one female having similar deletions were selected and crossed. Embryos were genotyped by fin clipping and genomic DNA extraction, followed by PCR amplification using the primers depicted in [Table S1](#mmc2){ref-type="supplementary-material"} (see also [Figure S4](#mmc1){ref-type="supplementary-material"}).

### Whole-mount *in situ* hybridization {#sec4.4.4}

Whole-mount *in situ* hybridization was performed on zebrafish embryos staged according to [@bib25], using antisense riboprobes targeting *nog2* or *insulin*. *nog2* probe was amplified from zebrafish cDNA, using the primers depicted in [Table S1](#mmc2){ref-type="supplementary-material"}, and cloned into pCR2.1-TOPO TA vector (ThermoFisher Scientific). A vector for generating an *insulin*-targeting probe was kindly sent to us by Francesco Argenton ([@bib1]). Vectors were linearized using HindIII restriction enzyme (ThermoFisher Scientific). Antisense RNA probes were synthesized, using T7 RNA polymerase (ThermoFisher Scientific) and digoxigenin-labeled nucleotides (Roche) and kept in ISH hybridization buffer (HYB+; [@bib51]). Zebrafish embryos were collected at 18 or 48hpf and fixed overnight in 4% paraformaldehyde (PFA) in phosphatebuffered saline (PBS). Fixed embryos were washed in PBS-Tween 0.1% (PBT) and dehydrated in methanol (MeOH), in a series of MeOH/PBT solutions. Dehydrated embryos were kept at −20°C in 100% MeOH. After this, embryos were rehydrated through a reverse MeOH/PBT series and then treated with proteinase K 1 mg/mL (ThermoFisher Scientific), for 1--10 min. Embryos were washed in PBT, post-fixed in 4% PFA for 20 min and washed again in PBT. Pre-hybridization was performed by incubating embryos in HYB+ buffer for 3 h, at 70°C. After that, hybridization buffer was replaced with solution containing riboprobes at the concentration of 2 ng/uL and an overnight incubation was performed, at 70°C. In the next day, embryos were washed with a series of solutions containing washing buffer (HYB-) and sodium saline citrate buffer (SSC), as described by [@bib51]. Embryos were incubated for 1 h in blocking buffer, containing 2% normal goat serum (ThermoFisher Scientific) and 2 mg/mL bovine serum albumin (BSA; Sigma-Aldrich). Following this, embryos were incubated for 2 h with anti-digoxigenin-AP antibody (Sigma-Aldrich) 1:5000, dissolved in blocking buffer. Several rinses in PBT were performed. In the third day, embryos were washed with alkaline-phosphatase (AP) buffer ([@bib51]) and AP activity was revealed through incubation in NBT/BCIP substrate (Sigma-Aldrich), in the dark, for at least 30 min. Embryos were rinsed in PBT to stop the reaction and kept in 100% glycerol at 4°C. Coloration associated to the presence of mRNA was observed and photographed, using the Leica M205 stereomicroscope. Post-imaging analysis was done in Fiji-ImageJ.

### Immunohistochemistry {#sec4.4.5}

Whole-mount immunohistochemistry was performed using mouse anti-rat nkx6.1 (Developmental Studies Hybridoma Bank) and rabbit anti-insulin (abcam) antisera. Goat antimouse IgG AlexaFluor 488 (Invitrogen), goat anti-rabbit IgG AlexaFluor 568 (Invitrogen) and goat anti-mouse IgG AlexaFluor 647 (Invitrogen) were used as secondary antisera. Briefly, embryos were fixed overnight in 4% paraformaldehyde (PFA) in phosphatebuffered saline (PBS). Fixed embryos were sequentially washed with PBS Triton 0.1%, then treated for 30 min to 2 h with PBS-Triton 1%, washed again with PBS-Triton 0.1% and incubated for 1h with PBS-T+BSA 5% before the incubation with the primary antisera, diluted 1:50 in PBS-T+BSA, overnight at 4°C. After extensive wash, embryos were incubated with the secondary antisera, overnight at 4°C, washed extensively and mounted in 50% glycerol in PBS. Embryos were stained with DAPI and 1,5 μm Z-series stacks were acquired on a Leica SP5 confocal microscope, using a 40x objective. Post-imaging analysis and quantifications were done in Fiji-ImageJ.

### Nog2 overexpression vector {#sec4.4.6}

The sequence encoding the signaling domain of the Nog2 protein was PCR amplified from zebrafish genomic DNA, using primers carrying adaptor ends for BamHI and NcoI restriction enzymes. The mature encoding *nog2* domain was amplified using 5′EcoRI and 3′ XhoI restriction sites. The PCR products were sequentially cloned into pCS2GFP ([@bib3]) by restriction enzyme cloning and the vector was sequenced. The *nog2 signaling_GFP_mature nog2* sequence was introduced into the \#237 pMEMCS vector of the tol2 kit ([@bib29]), by BamHI/ XhoI cloning. The minimal promoter--E3 enhancer cassette was obtained by BamHI/ SmaI digestion from the ZEDnog2E3 vector and cloned into the \#228 p5EMCS vector of the tol2 kit. The generated \#237 and \#228 vectors were recombined with the \#302 into the \#394 destination vector using recombination driven by clonase II.

### Morpholino injections {#sec4.4.7}

For the *nog2* knockdown, 25 nL of 1 mM solution of morpholino targeting *nog2* 5′UTR or *Danio rerio* standard control morpholino ([Table S1](#mmc2){ref-type="supplementary-material"}) (Gene tools, LLC) were injected in one-cell-stage Tg(ins:GFP) zebrafish embryos. Prior to the injection, morpholinos were incubated at 65°C for 10 min, vortexed, and diluted to 1mM in HyPure H20. Injected embryos were grown to 48 hpf and fixed overnight at 4°C in 4% paraformaldehyde in PBS. Fixed embryos were stained with DAPI and 1,5 μm Z-series stacks were acquired on a Leica SP5 confocal microscope, using a 40x objective. GFP + cells were counted using Fij-ImageJ. Embryos from 3 independent injections were analyzed for each condition.

### Nog2 mRNA injections {#sec4.4.8}

25 nL of an 8 ng/uL solution of Nog2 WT or Nog2^mut^ mRNAs were injected in one-cell-stage zebrafish embryos. Dorsalization phenotypes were observed and photographed around 24hpf, using the Leica M205 stereomicroscope. Post-imaging analysis was done in Fiji-ImageJ.

### 4C-seq {#sec4.4.9}

4C-seq was performed according with [@bib16], with minor alterations. For each replicate, at least 200 24hpf zebrafish embryos were collected. Embryos were fixed in 2% formaldehyde for 10 min, and stored at 80°C. Cell lysis was performed on ice, with a 15 mL Tenbroeck Homogenizer, not exceeding 10 min. Ligation was performed by using 60U T4 DNA Ligase (\#EL0012, ThermoFisher Scientific). Restriction enzymes used were DpnII (\#R0543M, NEB) and Csp6I (\#ER0211, ThermoScientific) for the first and second cuts, respectively. Chromatin was purified by Amicon Ultra15 Centrifugal Filter Device (Milipore). 4C libraries were prepared for Illumina sequencing by using Expand Long Template Polymerase (Roche) with primers targeting the TSSs of nog2 ([Table S1](#mmc2){ref-type="supplementary-material"}) and including Illumina adapters. Final PCR product was purified by High Pure PCR Product Purification Kit (Roche) and AMPure XP PCR purification kit (Agencourt AMPure XP). 4C-seq libraries were first inspected for quality control using FASTQC v.0.11.5 ([Data S1](#mmc3){ref-type="supplementary-material"}) and demultiplexed using the script "demultiplex.py" from the FourCSeq package ([@bib26]), allowing for 1 mismatch in the primer sequence. A custom perl script was used for subsequent processing, as previously described ([@bib56], [@bib57]). Shortly, reads were aligned to the zebrafish genome (Zv9/danRer7) using Bowtie ([@bib31]), keeping only uniquely mapping reads (v1.1.2, m 1). Reads within fragments flanked by restriction sites of the same enzyme, checked with BedTools ([@bib43]), or fragments smaller than 40 bp were filtered out. Mapped reads were then converted to readsperfirstenzymefragmentend units, and smoothed using a 30 fragment mean running window algorithm.

### Quantitative PCR {#sec4.4.10}

Total mRNA was extracted from batches of 30 embryos or single embryos at 12 hpf with TRIzol (Invitrogen) and subsequent phenol:chloroform purification. Total mRNA was used for reverse transcription with random primers (SuperScript II, Invitrogen). Quantitative PCR was performed on a BioRad CFX96 realtime system using Sybr (iSybr Green Supermix, BioRad), using the primers depicted in [Table S1](#mmc2){ref-type="supplementary-material"}. Each biological replicate was quantified in triplicates. eef1a and beta-actin or beta-actin alone were used as internal controls, and expression levels were compared using the DDCT method.

Quantification and Statistical Analysis {#sec4.5}
---------------------------------------

Assuming that the data are normally distributed, an unpaired t-test with Welch's correction was performed to test the significance of differences among sample averages. For the comparison of nog2 relative expression between single embryos, a Mann-Whitney test to compare ranks was used. Asterisks in each figure represent significance level: ^∗^p \< 0.05, ^∗∗^p \< 0,01, ^∗∗∗^p \< 0,001, n.s. = non-significant. Statistics and plots were done using GraphPad Prism 6.
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